alpha 1-Antitrypsin Deficiency
"alpha 1-Antitrypsin Deficiency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS.
| Descriptor ID |
D019896
|
| MeSH Number(s) |
C06.552.074 C08.381.112 C16.320.060 C23.550.325.500.500
|
| Concept/Terms |
alpha 1-Antitrypsin Deficiency- alpha 1-Antitrypsin Deficiency
- Deficiencies, alpha 1-Antitrypsin
- Deficiency, alpha 1-Antitrypsin
- alpha 1 Antitrypsin Deficiency
- alpha 1-Antitrypsin Deficiencies
|
Below are MeSH descriptors whose meaning is more general than "alpha 1-Antitrypsin Deficiency".
Below are MeSH descriptors whose meaning is more specific than "alpha 1-Antitrypsin Deficiency".
This graph shows the total number of publications written about "alpha 1-Antitrypsin Deficiency" by people in this website by year, and whether "alpha 1-Antitrypsin Deficiency" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 0 | 3 |
Below are the most recent publications written about "alpha 1-Antitrypsin Deficiency" by people in Profiles.
-
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct; 167(5):1008-1018.e5.
-
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease. Aliment Pharmacol Ther. 2024 05; 59(10):1183-1195.
-
Alpha-1 antitrypsin deficiency and pregnancy complications and birth outcomes: A population-based cohort study in Denmark. PLoS One. 2024; 19(1):e0296434.
-
Neonatal cholestasis in children with Alpha-1-AT deficiency is a risk for earlier severe liver disease with male predominance. Hepatol Commun. 2023 12 01; 7(12).
-
Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency. Pulm Pharmacol Ther. 2023 Dec; 83:102265.
-
Meta-analysis: Prevalence of significant or advanced fibrosis in adults with alpha-1-antitrypsin deficiency. Aliment Pharmacol Ther. 2023 07; 58(2):152-158.
-
Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif. Nat Nanotechnol. 2022 09; 17(9):1004-1014.
-
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med. 2022 08 11; 387(6):514-524.
-
Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency. Pulm Pharmacol Ther. 2022 06; 73-74:102124.
-
Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy. Int J Pharm. 2022 Jan 25; 612:121355.